Beyond the Wire: 3D-Printed Guide Promises New Standard in Breast Cancer Surgery

SEATTLE, WA – May 01, 2026 – A significant advance in the fight against breast cancer was unveiled today as med-tech innovator Cairn Surgical announced overwhelmingly positive results from a pivotal trial of its Breast Cancer Locator (BCL) System. The findings, presented at the annual meeting of the American Society of Breast Surgeons, demonstrate that the novel 3D-printed surgical guide dramatically reduces the need for repeat surgeries, a common and distressing issue for patients undergoing breast-conserving procedures.

The international, multicenter trial reported that the BCL System led to a 32% reduction in positive margin rates and, consequently, a 34% decrease in re-excisions—follow-up operations required when a tumor is not completely removed. This development marks a potential paradigm shift away from decades-old localization techniques toward a more personalized and precise surgical approach.

The Lingering Challenge of Positive Margins

For thousands of women who opt for a lumpectomy, or breast-conserving surgery, the primary goal is the complete removal of cancerous tissue while preserving as much healthy breast as possible. However, surgeons have long grappled with a persistent challenge: positive margins. This occurs when microscopic cancer cells are found at the very edge of the removed tissue specimen, indicating that some of the tumor may have been left behind.

This complication is far from rare, affecting approximately 20% of all lumpectomy patients. The rate is even higher, between 30% and 40%, for patients with specific cancer types like ductal carcinoma in situ (DCIS) or invasive lobular cancer, which often have irregular, difficult-to-define shapes. A positive margin necessitates a second surgery, known as a re-excision, to remove more tissue and ensure the cancer is gone. This not only increases healthcare costs and surgical risks but also inflicts a significant emotional and psychological toll on patients who believed their initial surgery was behind them.

The traditional method for locating non-palpable tumors has been wire localization (WL), where a radiologist inserts a thin wire into the breast to guide the surgeon. While a long-standing practice, WL has notable drawbacks, including patient discomfort, the risk of the wire moving, and logistical challenges in coordinating the wire placement and the surgery on the same day.

A Personalized Blueprint for Precision

The Cairn Surgical BCL System is designed to overcome these limitations by providing surgeons with an unprecedented level of patient-specific detail. Instead of merely marking a spot, the system creates a comprehensive, 3D blueprint for the entire excision.

The process begins with a standard supine MRI, taken while the patient lies face-up in the same position they will be in for surgery. This imaging data is sent to Cairn Surgical, where engineers use it to design and 3D-print a customized guidance device. This device is a sterile, single-use guide that is uniquely shaped to fit perfectly onto the patient's breast.

Crucially, the guide contains several ports that precisely outline the tumor's unique three-dimensional shape and size, including a clear margin of healthy tissue. At the start of the operation, while the patient is under anesthesia, the surgeon places the BCL on the breast. Bracketing wires are then inserted through the guide's ports, creating a clear, physical boundary around the tumor. This gives the surgeon a tangible, real-time map to guide the excision, helping to ensure the entire tumor is removed in a single procedure.

Dr. Jennifer Gass, a Professor of Surgery at The Warren Alpert Medical School of Brown University and the trial's Principal Investigator, highlighted the system's impact. “The BCL System provided patient-specific information regarding the unique size, shape and location of each tumor, derived from supine MRI,” she commented in the press release. “Having detailed information about each tumor gave us information we could consider before and during each breast cancer surgery.”

The Economic and Patient Impact of Fewer Surgeries

The clinical benefits of a 34% reduction in re-excisions translate directly into significant economic and personal advantages. Re-operations are a major driver of cost in breast cancer care. Recent health economics research has shown that a single re-excision can add incremental costs ranging from over $8,500 for Medicare patients to more than $21,000 for those with commercial insurance, factoring in operating room time, hospital stays, and follow-up care. By preventing one in three of these repeat procedures, the BCL System could generate substantial savings for the healthcare system, aligning with the broader push towards value-based care.

Beyond the financial ledger, the impact on the patient experience is profound. The BCL system eliminates the need for a separate, often uncomfortable pre-operative wire insertion procedure. More importantly, it offers patients greater peace of mind and a higher probability of completing their surgical treatment in a single step. Avoiding a second surgery means less recovery time, reduced risk of complications, and a quicker return to normal life. Furthermore, by enabling more precise removal of only the necessary tissue, the technology holds the potential for better long-term cosmetic outcomes, a crucial factor in a patient's quality of life and psychological recovery.

From Clinical Trial to the Operating Table

With these robust pivotal trial results, Cairn Surgical is now focused on bringing its technology to the broader market. The BCL System is already commercially available in Europe, having secured a CE Mark, and is being evaluated in a post-market study there. In the United States, the system remains an investigational device, but the company has submitted a De Novo 510(k) application to the U.S. Food and Drug Administration (FDA) for marketing clearance.

The De Novo pathway is designed for novel medical devices that are not substantially equivalent to any legally marketed predicate. A successful review would establish a new device category and allow Cairn Surgical to commercialize the BCL System in the U.S. As surgeons and hospitals increasingly seek out technologies that improve outcomes and reduce costs, the BCL System's demonstrated ability to solve the persistent problem of positive margins could position it as a new standard of care in the surgical treatment of breast cancer.